EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|August 1, 2004
Separating fact from fiction
Victoria, British Columbia - Sometimes what we accept as fact isn't actually reality. The truth in pediatric dermatology is turning out to be a bit different in some conditions than was taken for granted just a few years ago.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5